Suraksha Diagnostic Ltd Upgraded to Hold as Technicals Improve and Valuation Adjusts

Technical Trends Shift to Mildly Bullish

The most significant catalyst for the upgrade is the change in Suraksha Diagnostic’s technical grade, which moved from a sideways trend to mildly bullish. Weekly technical indicators such as MACD, KST, Dow Theory, and On-Balance Volume (OBV) all reflect mild bullishness, suggesting a positive momentum shift in the near term. The weekly MACD and KST indicators have improved, signalling potential upward price movement, while the Dow Theory confirms this mild bullish trend on both weekly and monthly timeframes.

However, some caution remains as daily moving averages are mildly bearish, and the Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal. Bollinger Bands on the weekly chart are bullish, indicating price volatility is currently supportive of upward moves. This mixed technical picture suggests that while momentum is improving, investors should remain vigilant for potential short-term fluctuations.

Suraksha Diagnostic’s stock price closed at ₹290.80, down 5.20% on the day, with a 52-week range between ₹224.10 and ₹353.65. Despite the recent dip, the stock has outperformed the Sensex over multiple periods, delivering 2.65% returns over one week and 8.43% year-to-date, compared to Sensex declines of -3.19% and -12.51% respectively.

Valuation Reassessed from Attractive to Fair

Suraksha Diagnostic’s valuation grade has been downgraded from attractive to fair, reflecting a recalibration of its price multiples relative to earnings and enterprise value. The company currently trades at a price-to-earnings (PE) ratio of 45.91, which is elevated compared to some peers but still reasonable within the healthcare services sector. Its price-to-book value stands at 6.64, while enterprise value to EBIT and EBITDA ratios are 31.25 and 17.77 respectively, indicating a premium valuation but not excessively stretched.

Return on capital employed (ROCE) is a healthy 15.8%, and return on equity (ROE) is 13.86%, supporting the fair valuation stance. The enterprise value to capital employed ratio of 5.26 further confirms that the company is fairly priced relative to the capital it utilises. Compared to competitors such as KMC Speciality (fair valuation with PE of 40.95) and GPT Healthcare (attractive valuation with PE of 28.63), Suraksha Diagnostic sits in the mid-range, justifying the shift to a fair rating.

While the PEG ratio is reported as 0.00, indicating no meaningful growth adjustment, the company’s dividend yield is not available, which may be a consideration for income-focused investors.

Financial Trend: Mixed Signals Amidst Growth and Challenges

Financially, Suraksha Diagnostic has experienced a challenging quarter in Q3 FY25-26, with negative operating profit performance. Despite this, the company demonstrates a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.40 times, and an operating profit growth rate of 89.29% annually over the longer term. This suggests resilience and potential for recovery.

Profit growth over the past year has been robust at 34%, even though the stock’s price return was negative at -3.03%. This divergence indicates that the market has not fully priced in the company’s improving fundamentals. Institutional investors hold a significant 36.59% stake, which increased by 0.56% in the previous quarter, signalling confidence from sophisticated market participants.

However, some financial stress points remain. The operating profit to interest coverage ratio for the quarter is at a low 7.33 times, and the debt-equity ratio has risen to 0.51 times, the highest in recent periods. Interest expenses also increased to ₹3.16 crores in the quarter, which could pressure margins if not managed carefully.

Over the last three years, Suraksha Diagnostic has consistently underperformed the BSE500 benchmark, and its one-year return of -3.03% trails the Sensex’s -9.55%. This underperformance highlights the need for cautious optimism despite recent improvements.

Quality Assessment Remains Stable

The company’s quality grade remains steady, reflecting a balanced profile of operational efficiency, governance, and market positioning. Suraksha Diagnostic operates in the hospital and healthcare services sector, a space characterised by steady demand and long-term growth potential. Its micro-cap status implies higher volatility but also opportunities for significant appreciation if fundamentals improve further.

With a Mojo Grade upgraded from Sell to Hold, the company is now viewed as a moderate risk investment with potential upside, contingent on continued financial recovery and sustained technical momentum.

Investment Outlook and Considerations

Suraksha Diagnostic’s upgrade to Hold reflects a more balanced investment thesis. The technical indicators suggest improving momentum, while valuation metrics indicate the stock is fairly priced rather than undervalued. Financially, the company faces short-term challenges but benefits from strong institutional backing and a solid long-term growth trajectory.

Investors should weigh the company’s recent negative quarterly results and elevated debt metrics against its operational growth and improving technical signals. The stock’s underperformance relative to benchmarks over the past three years warrants caution, but the current rating upgrade signals that the company may be stabilising and poised for moderate recovery.

Given its micro-cap status, Suraksha Diagnostic remains a higher-risk investment, suitable for investors with a tolerance for volatility and a focus on healthcare sector opportunities. Monitoring upcoming quarterly results and technical developments will be crucial to reassessing the stock’s trajectory.

Summary of Key Metrics

Current Price: ₹290.80 | 52-Week High: ₹353.65 | 52-Week Low: ₹224.10

Mojo Score: 54.0 (Hold) | Previous Grade: Sell (as of 12 May 2026)

PE Ratio: 45.91 | Price to Book: 6.64 | EV/EBITDA: 17.77 | ROCE: 15.8% | ROE: 13.86%

Debt to EBITDA: 1.40 times | Debt-Equity Ratio: 0.51 times | Operating Profit Growth: 89.29% annually

Institutional Holdings: 36.59% (up 0.56% QoQ)

Suraksha Diagnostic Ltd’s recent upgrade to Hold by MarketsMOJO reflects a comprehensive reassessment across technical, valuation, financial, and quality parameters. While challenges remain, the company’s improving momentum and fair valuation provide a more balanced outlook for investors in the healthcare services sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →